most popular glp-1 drugs Market Industry Trends and Global Forecasts 2024-2035: Over 150 GLP-1 Drug Candidates in Development for Multiple Indications, Type 2 Diabetes and Obesity Drive GLP-1 Drug Development Boom GLP-1 Agonists Weight Loss Drugs
Description
Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials
Medicare has never paid for weight-loss drugs at scale
More and more evidence is showing that the use of DPP4 Inhibitors and GLP1 Receptor Agonists in combination, is a practice worth changing
Compliance-first.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gut enteroendocrine cells that modulates glucose metabolism by controlling insulin excretion and glucagon secretion and inhibits gastric emptying leading to decreased food intake, thus limiting weight gain
Most Medicaid programs cover GLP-1s for Type 2 diabetes, but weight loss coverage varies
